Neural markers of methylphenidate response in children with attention deficit hyperactivity disorder and the impact on executive function.

IF 3.2 3区 医学 Q2 PSYCHIATRY
Frontiers in Psychiatry Pub Date : 2025-03-13 eCollection Date: 2025-01-01 DOI:10.3389/fpsyt.2025.1475889
Anqi Wang, Hua Yang, Yue Yang, Jie Yang, Xiaowen Yang, Qianhui Wen, Qian Wang, Hao Liu, Rong Luo
{"title":"Neural markers of methylphenidate response in children with attention deficit hyperactivity disorder and the impact on executive function.","authors":"Anqi Wang, Hua Yang, Yue Yang, Jie Yang, Xiaowen Yang, Qianhui Wen, Qian Wang, Hao Liu, Rong Luo","doi":"10.3389/fpsyt.2025.1475889","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. A core cognitive deficit in ADHD is executive function (EF) impairment, which significantly impacts daily life. Methylphenidate (MPH) is a widely used first-line treatment for ADHD, but objective biomarkers to assess treatment response are lacking. The aim of this study was to investigate the effects of MPH on executive function and identify potential neural biomarkers of response in children with ADHD using electroencephalogram (EEG).</p><p><strong>Methods: </strong>A total of 26 boys with ADHD (mean age 8.64 ± 1.30 years) participated in the study. All participants were treated with 18 mg/day of oral extended-release MPH in the morning for 8 weeks. Executive function was assessed using the BRIEF2 and Digit Span Test (DST), and event-related potentials (ERP) were measured at baseline and after 8 weeks of MPH treatment.</p><p><strong>Results: </strong>After 8 weeks of MPH treatment, significant improvements were observed in several executive function domains. BRIEF2 scores, including inhibition, self-monitoring, shifting, emotional control, initiation, working memory, planning/organization, task monitoring, and material organization, were significantly reduced (<i>P</i> < 0.05). Behavioral performance in the Go/NoGo task also improved, with shorter correct response times and higher accuracy rates (<i>P</i> = 0.002, <i>P</i> = 0.009). EEG results revealed a reduction in Nogo-P300 latency at Fz, Cz and Pz compared to baseline (<i>P</i><0.05).</p><p><strong>Conclusions: </strong>The normalization of P300 latency following MPH treatment appears to be a reliable neural biomarker of positive treatment response in children with ADHD. MPH was associated with improvements in executive function, particularly in inhibitory control and working memory.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1475889"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fpsyt.2025.1475889","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. A core cognitive deficit in ADHD is executive function (EF) impairment, which significantly impacts daily life. Methylphenidate (MPH) is a widely used first-line treatment for ADHD, but objective biomarkers to assess treatment response are lacking. The aim of this study was to investigate the effects of MPH on executive function and identify potential neural biomarkers of response in children with ADHD using electroencephalogram (EEG).

Methods: A total of 26 boys with ADHD (mean age 8.64 ± 1.30 years) participated in the study. All participants were treated with 18 mg/day of oral extended-release MPH in the morning for 8 weeks. Executive function was assessed using the BRIEF2 and Digit Span Test (DST), and event-related potentials (ERP) were measured at baseline and after 8 weeks of MPH treatment.

Results: After 8 weeks of MPH treatment, significant improvements were observed in several executive function domains. BRIEF2 scores, including inhibition, self-monitoring, shifting, emotional control, initiation, working memory, planning/organization, task monitoring, and material organization, were significantly reduced (P < 0.05). Behavioral performance in the Go/NoGo task also improved, with shorter correct response times and higher accuracy rates (P = 0.002, P = 0.009). EEG results revealed a reduction in Nogo-P300 latency at Fz, Cz and Pz compared to baseline (P<0.05).

Conclusions: The normalization of P300 latency following MPH treatment appears to be a reliable neural biomarker of positive treatment response in children with ADHD. MPH was associated with improvements in executive function, particularly in inhibitory control and working memory.

注意缺陷多动障碍儿童哌甲酯反应的神经标志物及其对执行功能的影响。
背景:注意缺陷多动障碍(ADHD)是一种常见的以注意力不集中、多动和冲动为特征的神经发育障碍。ADHD的核心认知缺陷是执行功能(EF)障碍,严重影响日常生活。哌醋甲酯(MPH)是一种广泛使用的治疗多动症的一线药物,但缺乏客观的生物标志物来评估治疗反应。本研究的目的是利用脑电图(EEG)研究MPH对ADHD儿童执行功能的影响,并确定潜在的神经生物标志物。方法:共26例ADHD男孩(平均年龄8.64±1.30岁)参与研究。所有参与者在早上口服缓释MPH 18mg /天,持续8周。使用BRIEF2和数字广度测试(DST)评估执行功能,并在基线和MPH治疗8周后测量事件相关电位(ERP)。结果:8周MPH治疗后,在几个执行功能领域观察到显著改善。抑制、自我监控、转移、情绪控制、启动、工作记忆、计划/组织、任务监控、材料组织等指标的BRIEF2得分显著降低(P < 0.05)。Go/NoGo任务中的行为表现也有所改善,正确反应时间更短,准确率更高(P = 0.002, P = 0.009)。脑电图结果显示,与基线相比,Fz、Cz和Pz的Nogo-P300潜伏期减少(p结论:MPH治疗后P300潜伏期的正常化似乎是ADHD儿童治疗阳性反应的可靠神经生物标志物。MPH与执行功能的改善有关,特别是在抑制控制和工作记忆方面。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Psychiatry
Frontiers in Psychiatry Medicine-Psychiatry and Mental Health
CiteScore
6.20
自引率
8.50%
发文量
2813
审稿时长
14 weeks
期刊介绍: Frontiers in Psychiatry publishes rigorously peer-reviewed research across a wide spectrum of translational, basic and clinical research. Field Chief Editor Stefan Borgwardt at the University of Basel is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. The journal''s mission is to use translational approaches to improve therapeutic options for mental illness and consequently to improve patient treatment outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信